Head-to-head evidence
LY4050784 vs PRT3789
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: SMARCA2 · full Non-Small Cell Lung Cancer pipeline
LY4050784
Developed by Foghorn Therapeutics Inc. under a licence from Eli Lilly
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT06561685 (registry estimate)
PRT3789
Developed by Prelude Therapeutics
NCT05639751 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY4050784's landscape · PRT3789's landscape